CL2022002779A1 - Compuestos y métodos para modular el proceso de corte y empalme - Google Patents

Compuestos y métodos para modular el proceso de corte y empalme

Info

Publication number
CL2022002779A1
CL2022002779A1 CL2022002779A CL2022002779A CL2022002779A1 CL 2022002779 A1 CL2022002779 A1 CL 2022002779A1 CL 2022002779 A CL2022002779 A CL 2022002779A CL 2022002779 A CL2022002779 A CL 2022002779A CL 2022002779 A1 CL2022002779 A1 CL 2022002779A1
Authority
CL
Chile
Prior art keywords
modulate
methods
compounds
splicing process
splicing
Prior art date
Application number
CL2022002779A
Other languages
English (en)
Inventor
Reynolds Dominic
A Agrawal Anant
Vaillancourt Frederic
Smith Peter
Leger Serge
W Seiler Michael
Prajapati Sudeep
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of CL2022002779A1 publication Critical patent/CL2022002779A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Replacement Of Web Rolls (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención divulga compuestos y composiciones relacionadas que, entre otros, modulan el proceso de corte y empalme de ácidos nucleicos, por ejemplo, el corte y empalme de pre-ARNm, así como también métodos para su uso.
CL2022002779A 2020-04-08 2022-10-07 Compuestos y métodos para modular el proceso de corte y empalme CL2022002779A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063007327P 2020-04-08 2020-04-08
US202063043920P 2020-06-25 2020-06-25
US202063072873P 2020-08-31 2020-08-31
US202063126493P 2020-12-16 2020-12-16

Publications (1)

Publication Number Publication Date
CL2022002779A1 true CL2022002779A1 (es) 2023-04-28

Family

ID=75747105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002779A CL2022002779A1 (es) 2020-04-08 2022-10-07 Compuestos y métodos para modular el proceso de corte y empalme

Country Status (13)

Country Link
EP (2) EP4132935A1 (es)
JP (2) JP2023520924A (es)
KR (2) KR20230004575A (es)
CN (2) CN116096725A (es)
AU (2) AU2021253571A1 (es)
BR (2) BR112022020418A2 (es)
CA (2) CA3175205A1 (es)
CL (1) CL2022002779A1 (es)
CO (1) CO2022015926A2 (es)
CR (1) CR20220567A (es)
IL (1) IL297149A (es)
MX (2) MX2022012676A (es)
WO (2) WO2021207530A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661509A4 (en) 2017-08-04 2021-01-13 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE
TW202208358A (zh) 2020-05-13 2022-03-01 美商Ｃｈｄｉ基金會股份有限公司 用於治療亨汀頓舞蹈症之htt調節劑
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
KR20230157367A (ko) * 2021-03-17 2023-11-16 에프. 호프만-라 로슈 아게 신규 티아졸로피리미디논 유도체
WO2023064879A1 (en) * 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023097007A1 (en) * 2021-11-24 2023-06-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
WO2008057601A2 (en) * 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
WO2012009688A1 (en) * 2010-07-16 2012-01-19 Rockefeller University Organic compounds
KR102137087B1 (ko) 2012-02-10 2020-07-24 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
JP6884102B2 (ja) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
MX2021001091A (es) 2015-12-10 2022-04-26 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
CA3037642A1 (en) * 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
MX2019014875A (es) * 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
EP3661509A4 (en) 2017-08-04 2021-01-13 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤

Also Published As

Publication number Publication date
KR20230005210A (ko) 2023-01-09
WO2021207530A8 (en) 2021-12-02
MX2022012676A (es) 2023-01-11
JP2023520925A (ja) 2023-05-22
KR20230004575A (ko) 2023-01-06
EP4132935A1 (en) 2023-02-15
CN116096725A (zh) 2023-05-09
WO2021207530A1 (en) 2021-10-14
IL297149A (en) 2022-12-01
CN116134036A (zh) 2023-05-16
WO2021207550A1 (en) 2021-10-14
CO2022015926A2 (es) 2022-11-29
JP2023520924A (ja) 2023-05-22
EP4132936A1 (en) 2023-02-15
CR20220567A (es) 2023-01-13
AU2021251220A1 (en) 2022-11-03
MX2022012677A (es) 2023-01-11
BR112022020337A2 (pt) 2022-12-13
BR112022020418A2 (pt) 2023-05-02
CA3175193A1 (en) 2021-10-14
AU2021253571A1 (en) 2022-11-10
CA3175205A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CL2022002779A1 (es) Compuestos y métodos para modular el proceso de corte y empalme
CO2022013832A2 (es) Amidas heterocíclicas y su uso para modular el empalme
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CO2017011183A2 (es) Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación
BR112022017089A2 (pt) Derivados de piridazina para modular o splicing de ácido nucleico
DOP2017000298A (es) Reguladores de nrf2
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
UY36950A (es) Compuestos útiles como inhibidores de la interacción proteína-proteína pd-1/pd-l1 y cd80/pd-l1 y composiciones que los contienen
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CU20180027A7 (es) DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
CL2022002780A1 (es) Compuestos y métodos para modular el corte y empalme
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
ECSP17069696A (es) Compuestos novedosos
ECSP16074478A (es) Compuestos novedosos
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CU20160168A7 (es) Proceso para preparar cianhidrinas que contienen fósforo